Since 1986, over 100 therapeutic monoclonal antibodies (mAbs) have been approved in the US and/or EU, targeting cancer, inflammation, and autoimmune diseases. These large molecules, designed to modulate one or more aspects of the immune system, can cause complications in the same system they're designed to treat.
Understand the safety issues and learn about alternative strategies to anticipate the adverse effects mAbs may have on the immune system, including the use of personalized study designs to make your drug development program more efficient.
Matthieu Carrière, PhD
Head of Immunology Department, Charles River
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.